Introduction
The biological significance of the adaptive immune system is complex and spreads far beyond just infection control. [1] [2] [3] [4] The paramount role of the innate immune system in cardiovascular pathology is very well established with involvement of monocytes/macrophages in atherogenesis and post-injury tissue remodelling being classical examples. [5] [6] [7] However, limited data are available on the role of the adaptive immune system in cardiac pathophysiology. Lymphocytes have been found to be involved in atherosclerotic plaque formation, but their low (rather than high) counts are typically associated with poor outcome, for example in heart failure. [5, [8] [9] [10] Lymphocyte derived biomarkers, such as immunoglobulin free light chains (FLC) which are produced in excess during antibody production and released into the circulation, may help investigation of the adaptive immune response. [11] Monoclonal generation of FLC κ and λ is a well-known parameter of plasma cell disorders, such as myeloma. [12] Until recently, limited information was available on polyclonal combined FLC (cFLC, summation of FLC κ and λ) elevations, when there is no obvious predominance of either chain. Polyclonal rise of cFLC predominantly reflects activation and proliferation of B-lymphocytes, although it could be also secondary to their impaired removal by dysfunctional kidneys or reticulo-endothelial system. [13, 14] Elevation of polyclonal cFLC has been reported in inflammatory and autoimmune disorders, diabetes mellitus and chronic kidney disease. [15] [16] [17] [18] Also, high cFLC concentrations are associated with activity of autoimmune disorders characterised by B-cell activation, with clearly distinct kinetics for cFLC and a C-reactive protein (CRP), a marker predominantly related to inflammatory responses of innate immunity. [17, 19, 20] cFLC may thus be of clinical value as a biomarker
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ACCEPTED MANUSCRIPT 4 of the adaptive immunity state. Of note, both the innate and adaptive parts of the immune system work in close interaction. [21] Monocytes and their functional subsets represent a major cellular part of the innate immune system, but limited data are available on their relationship with cFLC. [22] High cFLC concentrations are highly predictive of mortality in the general population even after adjustment for age, gender and renal function. [23, 24] Raised cFLC were associated with cardiovascular mortality in patients with chronic kidney disease after accounting for CRP levels. [20] Given the pathophysiological relationships discussed above, this biomarker might be related to prognosis in patients with myocardial infarction (MI), there are no data on changes in cFLC in patients with MI at present.
In the present pilot study, we aimed to assess dynamic changes of cFLC levels in STEMI patients over 30 days and their relation to markers of innate immunity (monocyte subsets), inflammation (high sensitivity C-reactive protein [hsCRP]), and an index of renal function, cystatin C, and obtain data on their prognostic significance. cFLC levels in patients with STEMI were compared to levels in patients with stable coronary artery disease ('disease controls') and healthy subjects. Additionally, no STEMI patients had a history of previous MI or left ventricular dysfunction.

Longitudinal analysis
In patients with STEMI plasma markers were measured at four time-points: day 1 (during the first 24 h after primary percutaneous coronary intervention (PCI)), day 3, day 7 and day 30.
Eighteen patients did not complete follow-up due to withdrawal of consent or death. Thirty patients with cFLC levels available for all time points were included in the longitudinal analysis.
Blood samples were collected from all participants and plasma stored at -70 ºC for batched analysis. Fresh blood was used for haematological analysis and quantification of monocyte subsets as described previously. [26, 27] A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 6 All study patients received standard treatment according to current guidelines. [25] The study was performed in accordance with the Helsinki declaration and was approved by the Coventry Research Ethics Committee. All participants provided written informed consent.
Outcome analysis
The prognostic significance of cFLC levels in STEMI was assessed with the primary outcome defined as a composite of 'death, admission for ACS, newly diagnosed HF or HF related hospital admission or new PCI' and the secondary end-point of 'need for new PCI' during follow up.
Flow cytometry
Monocytes and their subsets, as cellular markers of innate immunity and inflammation, were 
Power calculation
As there are no data for FLC, we calculated that minimum number of participants required to achieve 80% power to detect changes of 0.5 standard deviation in non-classical monocytes subsets was n=35 for the cross-sectional study and n=25 for the longitudinal study.
Statistical analysis
Normal 
value (or a strong trends towards significant predictive value) in multivariate analysis.
Additionally the multivariable Cox regression analysis included cystatin C (a marker of renal function) and troponin concentrations (a marker of myocardial damage). Data analysis was carried out using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) and a two-sided p-value of <0.05 was considered statistically significant.
Results
The 3 patient groups were well matched for age, gender, current blood pressure level and body mass index, creatinine and estimated glomerular filtration rate (eGFR) ( Table 1) .
Patients with acute STEMI had increased counts of monocytes and neutrophils compared to other groups (p<0.001). Healthy controls included a smaller proportion of smokers than other groups (p<0.001).
Increased hsCRP and Cystatin C levels were evident in patients with acute STEMI compared to the control groups ( 
Longitudinal analysis
In STEMI patients there was a significant increase in cFLC during the period of observation with highest values seen on day 7 post MI (p<0.001 vs. day 1) with increased levels persisting at day 30 (p<0.001 vs. day 1) (Table 2 Figure 1 ). hsCRP concentrations peaked on day 3 of the MI followed by their gradual reduction to the levels seen in controls (p<0.001).
Cystatin C concentrations were significantly increased (as compared to day 1) values on day
Outcome analysis
Sixteen primary outcome events were recorded during a (median) follow up period of 39 [19- 43] months ( (Figure 2 ).
Discussion
This pilot study provides the first analysis of cFLC in patients with STEMI. During acute phase of the disease cFLC values were similar to those in stable CAD and healthy individuals. However cFLC levels showed a relatively small but significant increase during the follow up period with peak concentrations determined on day 7 and were still increased on day 30. Secondly, cFLC concentrations measured at presentation were associated with an increased risk for new PCI even on multivariate analysis.
Median cFLC concentrations remained within the normal range even at day 7 post MI;
however the analysis matched the data from individual patients and showed a highly statistically significant and consistent increase in most patients, as shown in figure 1 
Limitations
This pilot study is relatively small and has limited power to establish the prognostic role of cFLC in STEMI, but allows hypothesis generation. Also, our data provide only limited information on possible mechanisms related to changes in cFLC post-MI and specifically designed pathophysiological studies will be required to address the issue.
In conclusion, cFLC levels increase during STEMI with peak values on day 7 after presentation and on multivariate analysis, predict the need for future PCI. The precise pathophysiological and clinical significance of this phenomenon remains unclear but may reflect post-STEMI inflammatory responses or renal reserve changes in these patients, which deserve further exploration. hsCRP, high sensitivity C-reactive protein. 
